A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors
Titel:
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors
Auteur:
Gordon, Michael S. Ilaria, Robert Alwis, Dinesh P. de Mendelson, David S. McKane, Scott Wagner, Margaret M. Look, Katherine Y. LoRusso, Patricia M.